Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines

Journal of Neuro-Oncology

Volumn 109, Issue 1, 2012, Pages 45-52

  Beier, Dagmar ^a,b   Schriefer, Beate ^b   Brawanski, Konstantin ^b   Hau, Peter ^b   Weis, Joachim ^a   Schulz, Jörg B ^a   Beier, Christoph P ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Glioblastoma cancer stem cell; MGMT; Temozolomide; Temozolomide rechallenge

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; CANCER STEM CELL; CELL GROWTH; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CLONOGENESIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPLETION; DOSE RESPONSE; DRUG CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS;

EID: 84864280546     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0878-4     Document Type: Article

References (31)

1. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
2. CP Beier C Schmid T Gorlia C Kleinletzenberger D Beier O Grauer A Steinbrecher B Hirschmann A Brawanski C Dietmaier T Jauch-Worley T Pietsch M Proescholdt P Rummele A Muigg G Stockhammer M Hegi U Bogdahn P Hau 2009 RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma-a phase II study BMC Cancer 9 308 19725960 10.1186/1471-2407-9-308
3. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
4. M Brada I Judson P Beale S Moore P Reidenberg P Statkevich M Dugan V Batra D Cutler 1999 Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies Br J Cancer 81 1022 1030 10576660 10.1038/sj.bjc.6690802 1:CAS:528:DyaK1MXnvFSjsLw%3D (Pubitemid 29516147)
5. L Rosso CS Brock JM Gallo A Saleem PM Price FE Turkheimer EO Aboagye 2009 A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients Cancer Res 69 120 127 19117994 10.1158/0008-5472.CAN-08-2356 1:CAS:528:DC%2BD1MXmvFem
6. JA Quinn SX Jiang DA Reardon A Desjardins JJ Vredenburgh JN Rich S Gururangan AH Friedman DD Bigner JH Sampson RE McLendon JE Herndon A Walker HS Friedman 2009 Phase II trial of temozolomide plus O-6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol 27 1262 1267 19204199 10.1200/JCO.2008.18.8417 1:CAS:528:DC%2BD1MXktFKhsLY%3D
7. D Beier S Rohrl DR Pillai S Schwarz LA Kunz-Schughart P Leukel M Proescholdt A Brawanski U Bogdahn A Trampe-Kieslich B Giebel J Wischhusen G Reifenberger P Hau CP Beier 2008 Temozolomide preferentially depletes cancer stem cells in glioblastoma Cancer Res 68 5706 5715 18632623 10.1158/0008-5472. CAN-07-6878 1:CAS:528:DC%2BD1cXovVCns7w%3D
8. SR Wedge JK Porteous BL May ES Newlands 1996 Potentiation of temozolomide and BCNU cytotoxicity by O-6-benzylguanine: a comparative study in vitro Br J Cancer 73 482 490 8595163 10.1038/bjc.1996.85 1:CAS:528:DyaK28Xhs1Kjtrg%3D (Pubitemid 26056467)
9. GP Margison AC Povey B Kaina MFS Koref 2003 Variability and regulation of O-6-alkylguanine-DNA alkyltransferase Carcinogenesis 24 625 635 12727789 10.1093/carcin/bgg005 1:CAS:528:DC%2BD3sXjslWhtrk%3D (Pubitemid 36592396)
10. AW Tolcher SL Gerson L Denis C Geyer LA Hammond A Patnaik AD Goetz G Schwartz T Edwards L Reyderman P Statkevich DL Cutler EK Rowinsky 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 1004 1011 12671695 10.1038/sj.bjc.6600827 1:CAS:528:DC%2BD3sXisFahtrY%3D (Pubitemid 36560766)
11. TP Spiro L Liu S Majka J Haaga JK Willson SL Gerson 2001 Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase Clin Cancer Res 7 2309 2317 11489806 1:CAS:528:DC%2BD3MXmsVOmt74%3D (Pubitemid 32751629)
12. AA Brandes A Tosoni G Cavallo R Bertorelle V Gioia E Franceschi M Biscuola V Blatt L Crino M Ermani 2006 Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 1155 1160 17024124 10.1038/sj.bjc.6603376 1:CAS:528:DC%2BD28XhtFChs73O (Pubitemid 44658477)
13. A Wick J Felsberg JP Steinbach U Herrlinger M Platten B Blaschke R Meyermann G Reifenberger M Weller W Wick 2007 Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma J Clin Oncol 25 3357 3361 17664483 10.1200/JCO.2007.10.7722 1:CAS:528: DC%2BD2sXhtVWqs7nO (Pubitemid 47325623)
14. AM Spence HP Kiem S Partap S Schuetze JR Silber RA Peterson 2006 Complications of a temozolomide overdose: a case report J Neurooncol 80 57 61 16645714 10.1007/s11060-006-9152-y (Pubitemid 44473262)
15. Blough MD, Westgate MR, Beauchamp D, Kelly JJ, Stechishin O, Ramirez AL, Weiss S, Cairncross JG (2010) Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol 12(7):756-760
16. AM Mihaliak CA Gilbert L Li MC Daou RP Moser A Reeves BH Cochran AH Ross 2010 Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres Cancer Lett 296 168 177 20435409 10.1016/j.canlet.2010.04.005 1:CAS:528:DC%2BC3cXpsFOqurw%3D
17. AM Bleau D Hambardzumyan T Ozawa EI Fomchenko JT Huse CW Brennan EC Holland 2009 PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells Cell Stem Cell 4 226 235 19265662 10.1016/j.stem.2009.01.007 1:CAS:528:DC%2BD1MXjvVSqsLg%3D
18. G Liu X Yuan Z Zeng P Tunici H Ng 2006 Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Mol Cancer 5 67 17140455 10.1186/1476-4598-5- 67 (Pubitemid 44942887)
19. SM Pollard K Yoshikawa ID Clarke D Danovi S Stricker R Russell J Bayani R Head M Lee M Bernstein JA Squire A Smith P Dirks 2009 Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens Cell Stem Cell 4 568 580 19497285 10.1016/j.stem.2009.03.014 1:CAS:528:DC%2BD1MXnt1Ggtbg%3D
20. A Li J Walling Y Kotliarov A Center ME Steed SJ Ahn M Rosenblum T Mikkelsen JC Zenklusen HA Fine 2008 Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas Mol Cancer Res 6 21 30 18184972 10.1158/1541-7786.MCR-07-0280 1:CAS:528:DC%2BD1cXhtFyisbk%3D (Pubitemid 351378163)
21. D Beier P Hau M Proescholdt A Lohmeier J Wischhusen PJ Oefner L Aigner A Brawanski U Bogdahn CP Beier 2007 CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles Cancer Res 67 4010 4015 17483311 10.1158/0008-5472.CAN-06-4180 1:CAS:528:DC%2BD2sXltVyku74%3D (Pubitemid 46815044)
22. JR Perry K Belanger WP Mason D Fulton P Kavan J Easaw C Shields S Kirby DR Macdonald DD Eisenstat B Thiessen P Forsyth JF Pouliot 2010 Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 2051 2057 20308655 10.1200/JCO.2009.26.5520 1:CAS:528:DC%2BC3cXmtlSksrk%3D
23. WP Roos LF Batista SC Naumann W Wick M Weller CF Menck B Kaina 2007 Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine Oncogene 26 186 197 16819506 10.1038/sj.onc.1209785 1:CAS:528:DC%2BD2sXjsFOlsQ%3D%3D (Pubitemid 46095730)
24. Y Hirose MS Berger RO Pieper 2001 p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells Cancer Res 61 1957 1963 11280752 1:CAS:528:DC%2BD3MXit1Ogsrk%3D (Pubitemid 32692013)
25. JR Perry P Rizek R Cashman M Morrison T Morrison 2008 Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach Cancer 113 2152 2157 18756530 10.1002/cncr.23813 1:CAS:528:DC%2BD1cXht12lu77J
26. J Lee S Kotliarova Y Kotliarov A Li Q Su NM Donin S Pastorino BW Purow N Christopher W Zhang JK Park HA Fine 2006 Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines Cancer Cell 9 391 403 16697959 10.1016/j.ccr.2006.03.030 1:CAS:528:DC%2BD28XltF2nsLk%3D (Pubitemid 43668737)
27. C Lottaz D Beier K Meyer P Kumar A Hermann J Schwarz M Junker PJ Oefner U Bogdahn J Wischhusen R Spang A Storch CP Beier 2010 Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin Cancer Res 70 2030 2040 20145155 10.1158/0008-5472.CAN-09-1707 1:CAS:528:DC%2BC3cXisFWis74%3D
28. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP (2011) RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol (Meeting Abstracts) 29:15-suppl
29. R Stupp ME Hegi B Neyns R Goldbrunner U Schlegel PM Clement GG Grabenbauer AF Ochsenbein M Simon PY Dietrich T Pietsch C Hicking JC Tonn AC Diserens A Pica M Hermisson S Krueger M Picard M Weller 2010 Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 2712 2718 20439646 10.1200/JCO.2009.26. 6650 1:CAS:528:DC%2BC3cXoslyktLs%3D
30. D Beier 2011 Schulz JB, Beier CP: Chemoresistance of glioblastoma cancer stem cells - much more complex than expected Mol Cancer 10 128 21988793 10.1186/1476-4598-10-128 1:CAS:528:DC%2BC3MXhs1Oht7nF
31. W Wick JP Steinbach WM Kuker J Dichgans M Bamberg M Weller 2004 One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma Neurology 62 2113 2115 15184628 10.1212/01.WNL.0000127617.89363.84 1:CAS:528:DC%2BD2cXktVKgtrs%3D (Pubitemid 38738235)